# US 2017/0320828 A1 · Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0320828 A1
- Document ID: US20170320828A1
- Status: Published application
- Kind: A1
- Application number: 15/495,670
- Filed: 2017-04-24
- Published: 2017-11-09
- Earliest claimed: 2013-03-14
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Wenjin Yang; Che-Hong Chen; Daria Mochly-Rosen
- Web page: https://patentgrep.com/patent/US20170320828A1

## CPC

- C07D 213/82: in position 3
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 25/32: Alcohol-abuse
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61P 35/00: Antineoplastic agents
- C07C 233/66: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C 233/73: of a carbon skeleton containing six-membered aromatic rings
- C07C 233/78: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C 233/87: of a carbon skeleton containing six-membered aromatic rings
- C07C 235/48: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 235/60: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 237/32: having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
- C07C 311/16: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C 311/17: to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 311/40: to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 317/32: with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07D 213/81: Amides; Imides
- C07D 213/89: with hetero atoms directly attached to the ring nitrogen atom
- C07D 317/58: Radicals substituted by nitrogen atoms (nitro radicals C07D317/52)
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/08: the ring being saturated
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

## Claims

### Claim 1

A compound of formula:
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein
A is selected from C and S;
X2 is selected from CR2, N, and NO;
X3 is selected from CR3, N, and NO;
X4 is selected from CR4, N, and NO;
Xd is selected from CRd, N, and NO;
Ra, Rb, Rc, Rd, and Re are independently selected from hydrogen, halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, NH2, NO2, NHR6, NR6R6, S(O)pR6, C(O)R6, C(O)OR6, CF3, CF2H, CFH2, OCF3, OCF2H, and OCFH2;
alternatively, Rb and Rc together form a 3-14 membered saturated, partially saturated, or unsaturated heterocycle containing one or more heteroatoms selected from N, O, and S; wherein the heterocycle is optionally substituted with one or more R8;
Rf, Rg, and Rb are independently selected from hydrogen and C1-C6 alkyl;
R1, R2, R3, R4, and R5 are independently selected from hydrogen, halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, OR7, NH2, NO2, NHR7, NR7R7, S(O)qR7, C(O)R7, C(O)OR7, CF3, CF2H, CFH2, OCF3, OCF2H, and OCFH2;
R6 is selected from hydrogen and C1-C6 alkyl;
R7 is selected from (a) hydrogen, (b) C1-C6 alkyl, (c) C2-C6 alkenyl, (d) C2-C6 alkynyl, (e) 3-14 membered saturated, partially saturated, or unsaturated carbocycle, and (f) 3-14 membered saturated, partially saturated, or unsaturated heterocycle containing one or more heteroatoms selected from N, O, and S;
wherein (b)-(f) optionally is substituted with one or more R8;
R8 is selected from (a) halogen, (b) OH, (c) NO2, (c) NH2, (d) C(O)OH, (e) NH(C1-C6 alkyl), (f) N(C1-C6 alkyl)2, (g) C(O)O—(C1-C6 alkyl), (h) C1-C6 alkyl, (i) C1-C6 alkoxy, (j) 3-14 membered saturated, partially saturated, or unsaturated carbocycle, (k) 3-14 membered saturated, partially saturated, or unsaturated heterocycle containing one or more heteroatoms selected from N, O, and S; and (l) ═O
wherein (e)-(k) optionally is substituted with one or more R9;
R9 is selected from halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, C(O)OH, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NO2, and S(O)q—(C1-C6 alkyl);
n is 1 or 2;
p is 1 or 2;
q is 0, 1, or 2;
provided that
and
provided that the compound is not selected from:
or a compound of formula (V):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein
W is selected from C and S;
Y2 is selected from CR2y, N, and NO;
Y3 is selected from CR3y, N, and NO;
Y4 is selected from CR4yR4y and NR4y;
Y5 is selected from CR5yR5y and NR5y;
R1y, R2y, R3y, R4y, and R5y are independently selected from (a) hydrogen, (b) halogen, (c) OH, (d) C1-C6 alkyl, (e) C1-C6 alkoxy, (f) OR9y, (g) NH2, (h) NO2, (i) NHR9y, (j) NR9yR9y, (k) S(O)tR9y, (l) C(O)R9y, (m) C(O)OR9y, (n) CF3, (o) CF2H, (p) CFH2, (q) OCF3, (r) OCF2H, (s) OCFH2, (t) (CH2)u-3-14 membered saturated, partially saturated, or unsaturated carbocycle, and (u) (CH2)v-3-14 membered saturated, partially saturated, or unsaturated heterocycle containing one or more heteroatoms selected from N, O, and S;
wherein (t)-(u) optionally is substituted with R10y;
alternatively, two R4y or two R5y together form a ═O;
R6y is selected from hydrogen and C1-C6 alkyl;
R7y and R8y are independently selected from halogen, OH, NO2, NH2, C(O)OH, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, C(O)O—(C1-C6 alkyl), C1-C6 alkyl, C1-C6 alkoxy, CF3, CF2H, CFH2, OCF3, OCF2H, and OCFH2;
R9y is selected from halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, C(O)OH, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NO2, and S(O)t—(C1-C6 alkyl);
R10y is selected from halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, C(O)OH, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NO2, CF3, CF2H, CFH2, OCF3, OCF2H, and OCFH2
m is 1 or 2;
t is 0, 1, or 2;
u is 0, 1, 2, 3, 4, 5, or 6; and
v is 0, 1, 2, 3, 4, 5, or 6;
or a compound chosen from:

### Claim at position 2

-30. (canceled)

### Claim 31

A method of administering a compound to a subject, the method comprising:
administering to a subject in need thereof an effective amount of a compound of formula:
or a pharmaceutically acceptable salt or solvate thereof, wherein
A is C;
X2 is CR2;
X3 is CR3;
X4 is selected from N and NO;
Xd is CRd;
Ra, Rb, Rd, and Re are independently selected from hydrogen, halogen, OH, C1-C6 alkyl, and C1-C6 alkoxy
Rc is selected from OH, C1-C6 alkoxy, OCF3, OCF2H, and OCFH2;
Rf, Rg, and Rb are independently selected from hydrogen and C1-C6 alkyl;
R1 is halogen;
R2 and R3 are independently selected from hydrogen, halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, OR7, NH2, NO2, NHR7, NR7R7, S(O)qR7, C(O)R7, C(O)OR7, CF3, CF2H, CFH2, OCF3, OCF2H, and OCFH2;
R5 is selected from halogen, C1-C6 alkyl, OR7, and NHR7;
R6 is selected from hydrogen and C1-C6 alkyl;
R7 is selected from (a) hydrogen, (b) C1-C6 alkyl, (c) C2-C6 alkenyl, (d) C2-C6 alkenyl, (e) 3-14 membered saturated, partially saturated, or unsaturated carbocycle, and (f) 3-14 membered saturated, partially saturated, or unsaturated heterocycle containing one or more heteroatoms selected from N, O, and S;
wherein (b)-(f) optionally is substituted with one or more R8;
R8 is selected from (a) halogen, (b) OH, (c) NO2, (c) NH2, (d) C(O)OH, (e) NH(C1-C6 alkyl), (f) N(C1-C6 alkyl)2, (g) C(O)O—(C1-C6 alkyl), (h) C1-C6 alkyl, C1-C6 alkyl, (i) C1-C6 alkoxy, (j) 3-14 membered saturated, partially saturated, or unsaturated carbocycle, (k) 3-14 membered saturated, partially saturated, or unsaturated heterocycle containing one or more heteroatoms selected from N, O, and S; and (l) ═O
wherein (e)-(k) optionally is substituted with one or more R9;
R9 is selected from halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, C(O)OH, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NO2, and S(O)q—(C1-C6 alkyl);
n is 1
p is 1 or 2; and
q is 0, 1, or 2.

### Claim 32 (depends on 31)

The method of claim 31, wherein the method is effective for treating or preventing alcohol intolerance, alcohol addiction, an alcohol abuse disorder, alcohol intoxication, alcohol dependence, alcohol poisoning, or symptoms of alcohol consumption in the subject.

### Claim 33 (depends on 32)

The method of claim 32, wherein the alcohol poisoning is methanol poisoning.

### Claim 34 (depends on 33)

The method of claim 33, wherein the alcohol poisoning is acute alcohol poisoning.

### Claim 35 (depends on 34)

The method of claim 34, wherein the alcohol intoxication is acute alcohol intoxication.

### Claim 36 (depends on 32)

The method of claim 32, wherein the symptom of alcohol consumption is a hangover symptom.

### Claim 37 (depends on 36)

The method of claim 36, wherein the hangover symptom is selected from a group consisting of dehydration, fatigue, headache, body aches, vomiting, diarrhea, flatulence, weakness, elevated body temperature and heart rate, hypersalivation, difficulty concentrating, sweating, anxiety, dysphoria, irritability, sensitivity to light and noise, erratic motor function, trouble sleeping, severe hunger, halitosis, and lack of depth perception.

### Claim 38 (depends on 32)

The method of claim 32, further comprising an opioid receptor antagonist.

### Claim 39 (depends on 38)

The method of claim 38, wherein the opioid receptor antagonist is naltrexone.

### Claim 40 (depends on 31)

The method of claim 31, wherein the method is effective for sequestering aldehyde in a subject exposed to alcohol or aldehyde.

### Claim 41 (depends on 31)

The method of claim 31, wherein the method is effective for reducing a level of an aldehyde present at a toxic level in the subject to below the toxic level, wherein the aldehyde is a biogenic aldehyde or a xenogenic aldehyde.

### Claim 42 (depends on 41)

The method of claim 41, wherein the biogenic aldehyde is acetaldehyde, malondialdehyde (MDA), 3,4-dihydroxypheylacetaldehyde (DOPAL), 3,4-dihydroxyphenylglycolaldehye (DOPEGAL), hexanal, acrolein, glyoxal, crotonaldehyde, trans-2-nonenal, 4-oxo-2-nonenal, or 4-hydroxy-2-nonenal (HNE).

### Claim 43 (depends on 41)

The method of claim 41, wherein the xenogenic aldehyde is an environmental aldehyde that is ingested or inhaled.

### Claim 44 (depends on 31)

The method of claim 31, wherein the method is effective for treating or preventing an acute or a chronic free-radical associated disease in the subject.

### Claim 45 (depends on 44)

The method of claim 44, wherein the acute free-radical associated disease is selected from seizures and photo-damage to the skin.

### Claim 46 (depends on 31)

The method of claim 31, wherein the method is effective for treating or preventing an ocular disorder in the subject.

### Claim 47 (depends on 46)

The method of claim 46, wherein the ocular disorder is selected from age-related cataracts, secondary cataracts, traumatic cataracts, congenital cataracts, age-related macular degeneration, and radiation cataracts.

### Claim 48 (depends on 31)

The method of claim 31, wherein the method is effective for treating or preventing radiation-induced damage to epithelial cells in the subject.

### Claim 49 (depends on 48)

The method of claim 48, wherein the radiation-induced damage results in radiation dermatitis.

### Claim 50 (depends on 48)

The method of claim 48, wherein the compound or pharmaceutical composition is to be administered before the subject is exposed to ionizing radiation.

### Claim 51 (depends on 48)

The method of claim 48, wherein the compound or pharmaceutical composition is to be administered after the subject is exposed to ionizing radiation.

### Claim 52 (depends on 48)

The method of claim 48, wherein the compound or pharmaceutical composition is to be administered both before and after the subject is exposed to ionizing radiation.

### Claim 53 (depends on 48)

The method of claim 48, wherein the radiation-induced damage results in mucositis.

### Claim 54 (depends on 48)

The method of claim 48, wherein the compound or pharmaceutical composition is to be administered to a mucosal surface in the subject.

### Claim 55 (depends on 31)

The method of claim 31, wherein the method is effective for reducing the likelihood that the subject will develop head and neck cancer.

### Claim 56 (depends on 55)

The method of claim 55, wherein the subject is a habitual use of betel quid.

### Claim 57 (depends on 56)

The method of claim 56, wherein the composition is a toothpaste, a tooth gel, a tooth powder, a mouth rinse, a chewing gum, or a lozenge.

### Claim 58 (depends on 31)

The method of claim 31, wherein the method is effective for treating or preventing cancer in the subject, the method further comprises administering to the subject a cancer chemotherapeutic agent or ionizing radiation, wherein the compound and the cancer chemotherapeutic agent, or the compound and the ionizing radiation, are administered in combined effective amounts to treat or prevent the cancer in the subject.

### Claim 59 (depends on 58)

The method of claim 58, wherein the chemotherapeutic agent is selected from an alkylating agent, a nitrosourea, an antimetabolite, an antitumor antibiotic, a plant (vinca) alkaloid, and a steroid hormone.

### Claim 60 (depends on 59)

The method of claim 59, wherein the alkylating agent is selected from nitrogen mustards, nitrosoureas, ethylenimine derivatives, alkyl sulfonates, and triazenes, including, but not limited to, mechlorethamine, cyclophosphamide, melphalan (L-sarcolysin), carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU), streptozocin, chlorozotocin, uracil mustard, chlormethine, ifosfamide, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, dacarbazine, and temozolomide.

### Claim 61 (depends on 58)

The method of claim 58, wherein the ionizing radiation is external beam radiation therapy or brachytherapy.

### Claim 62 (depends on 58)

The method of claim 58, wherein the compound or pharmaceutical composition reduces the amount of the chemotherapeutic agent or the ionizing radiation required to treat or prevent the cancer.

### Claim 63 (depends on 31)

The method of claim 31, wherein the method is effective for reducing the likelihood that the subject will develop oral cancer or lung cancer.

### Claim 64 (depends on 31)

The method of claim 31, wherein the compound or pharmaceutical composition is to be administered by a route selected from intramuscular, intravenous, subcutaneous, topical, and oral.

### Claim 65

(canceled)
